Moreover, GLP-1R agonists suppress inflammation induced by cytokines produced in epicardial adipose tissue, which directly contributes to reduced risk of myocardial dysfunction and following cardiomyopathy. This evidence concerns the gene GLP1R and cardiomyopathy.